We are live on ! Find out more
CRSP icon

CRISPR Therapeutics
CRSP

174 hedge funds and large institutions have $1.09B invested in CRISPR Therapeutics in 2018 Q2 according to their latest regulatory filings, with 70 funds opening new positions, 52 increasing their positions, 32 reducing their positions, and 30 closing their positions.

New
Increased
Maintained
Reduced
Closed

133% more first-time investments, than exits

New positions opened: 70 | Existing positions closed: 30

63% more repeat investments, than reductions

Existing positions increased: 52 | Existing positions reduced: 32

29% more funds holding

Funds holding: 135 → 174 (+39)

27% more capital invested

Capital invested by funds: $855M → $1.09B (+$232M)

0.64% less ownership

Funds ownership: 39.84% → 39.2% (-0.64%)

20% less funds holding in top 10

Funds holding in top 10: 5 → 4 (-1)

66% less call options, than puts

Call options by funds: $29.7M | Put options by funds: $86.8M

Holders
174
Holders Change
+39
Holders Change %
+28.89%
% of All Funds
3.98%
Holding in Top 10
4
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-20%
% of All Funds
0.09%
New
70
Increased
52
Reduced
32
Closed
30
Calls
$29.7M
Puts
$86.8M
Net Calls
-$57.1M
Net Calls Change
-$35.1M

Top Buyers

1
Federated Hermes
Federated Hermes
Pennsylvania
+$36M
2
AIM
ARK Investment Management
Florida
+$22.5M
3
O
OrbiMed
New York
+$22.3M
4
Two Sigma Advisers
Two Sigma Advisers
New York
+$19M
5
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
+$12.9M

Top Sellers

1
NMC
NEA Management Company
Maryland
-$79.4M
2
VVM
Versant Venture Management
California
-$56.8M
3
A
Abingworth
United Kingdom
-$37M
4
MWNA
Marshall Wace North America
New York
-$21.8M
5
NHAS
Novo Holdings A/S
Denmark
-$10.2M
Name Holding Trade Value Shares
Change 		Change in
Stake
Capital World Investors
26
Capital World Investors
California
$8.11M – – –
Allianz Asset Management
27
Allianz Asset Management
Germany
$7.37M -$6.11M -107,287 -46%
AC
28
Armistice Capital
New York
$7.29M +$7.06M +124,000 New
CAI
29
Capital Advisors Inc
Oklahoma
$6.25M -$2.42M -42,476 -29%
Citadel Advisors
30
Citadel Advisors
Florida
$5.61M +$2.38M +41,785 +78%
GIM
31
Granahan Investment Management
Massachusetts
$5.57M +$458K +8,048 +9%
Bank of Montreal
32
Bank of Montreal
Ontario, Canada
$5.44M +$2.73M +47,850 +107%
NIP
33
Nicholas Investment Partners
California
$5.09M +$350K +6,143 +8%
First Trust Advisors
34
First Trust Advisors
Illinois
$5M +$4.85M +85,052 New
UBS Group
35
UBS Group
Switzerland
$4.85M +$1.32M +23,130 +39%
RJA
36
Raymond James & Associates
Florida
$4.81M -$29.9K -525 -0.6%
Invesco
37
Invesco
Georgia
$4.41M +$4.28M +75,075 New
IIM
38
Ipswich Investment Management
Massachusetts
$3.35M +$285 +5 +0%
WM
39
WS Management
Florida
$3.35M +$3.25M +57,000 New
Korea Investment Corp
40
Korea Investment Corp
South Korea
$3.28M +$3.18M +55,800 New
FCM
41
Frontier Capital Management
Massachusetts
$3.21M +$3.11M +54,631 New
Royal Bank of Canada
42
Royal Bank of Canada
Ontario, Canada
$3.17M +$1.55M +27,272 +102%
Two Sigma Investments
43
Two Sigma Investments
New York
$3.1M -$2.96M -51,958 -50%
JP Morgan Chase
44
JP Morgan Chase
New York
$3.1M +$3.01M +52,811 New
Goldman Sachs
45
Goldman Sachs
New York
$3.06M +$1.4M +24,516 +89%
ACM
46
Atika Capital Management
New York
$3.06M +$2.96M +52,000 New
Ameriprise
47
Ameriprise
Minnesota
$2.99M +$1.44M +25,269 +93%
AG
48
Artal Group
Luxembourg
$2.94M +$1.42M +25,000 +100%
Vanguard Group
49
Vanguard Group
Pennsylvania
$2.87M +$426K +7,479 +18%
CCI
50
Columbus Circle Investors
$2.8M +$2.71M +47,628 New
1
2
3 4 5

CRSP Hedge Fund Activity: Q2 2018 in Review

174 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in CRISPR Therapeutics (CRSP) for Q2 2018, worth a combined $1.09B — up 27% from $855M a quarter earlier.

Buyers outnumbered sellers: 70 funds opened new CRSP positions and 30 closed out — a net gain of 40 holders — while 52 added to existing stakes and 32 trimmed.

The largest buyer was Federated Hermes, opening a new position worth an estimated $36M. The largest seller was NEA Management Company, cutting an estimated $79.4M.

  • 174 institutional investors held CRISPR Therapeutics (CRSP) as of Q2 2018, up from 135 in Q1 2018.
  • Funds reported $1.09B of CRISPR Therapeutics stock for Q2 2018, up 27% quarter-over-quarter.
  • 70 funds opened new CRISPR Therapeutics positions in Q2 2018 and 30 closed out, a net change of +40 holders.
  • The largest CRISPR Therapeutics buyer in Q2 2018 was Federated Hermes, an estimated $36M added.
  • The largest CRISPR Therapeutics seller in Q2 2018 was NEA Management Company, an estimated $79.4M sold.

Based on aggregated 13F filings for Q2 2018.